What is the Granules India PE ratio today?
Granules India's PE ratio is 31.3 at the 29 October 2026 close (₹837.35 a share): a market capitalisation of ₹20,750 crore divided by consolidated net profit of ₹662 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹595 crore) it is 34.9.
What is the Granules India debt to equity ratio?
Granules India's debt-to-equity ratio was 0.26 on 31 March 2026: borrowings of ₹1,338 crore against total equity of ₹5,085 crore. A year earlier, on 31 March 2025, it was 0.35.
What is the Granules India net worth?
Granules India's net worth — shareholders' equity in its consolidated balance sheet — was ₹5,085 crore on 31 March 2026, up 36.9% from ₹3,716 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹20,750 crore at the 29 October 2026 close.
What is the Granules India PB ratio (price to book value)?
Granules India's price-to-book (PB) ratio is 4.08 at the 29 October 2026 close: a market capitalisation of ₹20,750 crore divided by shareholders' equity (book value) of ₹5,085 crore on 31 March 2026. That is a book value of ₹205.21 per share against a share price of ₹837.35.
What is the Granules India ROE and ROCE?
In FY26, Granules India's return on equity (ROE) was 13.5% and its return on capital employed (ROCE) was 18.0%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 14.5% and ROCE 18.7%.
What is the Granules India book value per share?
Granules India's book value per share was ₹205.21 on 31 March 2026: shareholders' equity of ₹5,085 crore divided by the 24.78 crore shares in issue, up 34.0% from ₹153.19 a year earlier. The share price at the 29 October 2026 close was ₹837.35.
What is the Granules India market cap?
Granules India's market capitalisation was ₹20,750 crore at the 29 October 2026 close: 24.78 crore shares at ₹837.35 each.
What is the Granules India EPS?
Granules India's basic earnings per share (EPS) were ₹24.47 in FY26, against ₹20.69 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹27.06.
What is the Granules India dividend in 2026 and its record date?
In 2026, Granules India has declared one dividend: ₹1.75 with record date 30 July 2026.
Is Granules India debt free?
No. Granules India had borrowings of ₹1,338 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.26. Its cash and current investments were ₹949 crore, so its net debt was ₹389 crore.
What is the Granules India dividend yield?
Granules India's dividend yield is 0.21% at the 29 October 2026 close: dividends of ₹1.75 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹837.35. They were ₹1.75 on 30 July 2026.
What is the Granules India promoter holding?
Promoters held 37.39% of Granules India on 30 September 2026, down 0.63 percentage points from 38.02% the previous quarter and down 1.43 percentage points from 38.82% a year earlier, according to the shareholding pattern filed with NSE.
What is the Granules India shareholding pattern?
On 30 September 2026, Granules India's shares were held by promoters 37.39%, foreign portfolio investors (FII/FPI) 20.25%, domestic institutions (DII) 15.33% (including mutual funds at 4.26%) and retail and other non-institutional investors 27.04%. Over the year, FII holding was up 6.16 percentage points from 14.09% and DII holding was down 2.59 percentage points from 17.92%.
What are the Granules India latest quarterly results?
Granules India's latest results are for Q1 FY27 (April–June 2026), filed on 21 July 2026: consolidated net profit ₹180 crore, up 63.0% from ₹110 crore in Q1 FY26; revenue from operations ₹1,477 crore, up 22.0% year on year.
How does the Granules India PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Granules India's PE ratio is 34.9, the second highest of the four: Aurobindo Pharma 27.3, Ipca Laboratories 42.8 and Aarti Drugs 21.0, a peer average of 30.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Granules India free cash flow?
In FY26, Granules India generated ₹793 crore of cash from operations and spent ₹558 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹235 crore. In FY25 it was ₹295 crore.
What is the Granules India revenue and profit in FY26?
In FY26 (April 2025–March 2026), Granules India's consolidated net profit was ₹595 crore, up 18.6% from ₹502 crore in FY25, on revenue from operations of ₹5,366 crore (up 19.7%). Over three years, from FY23, net profit was up 15.2%.
When are the Granules India next results?
Granules India will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
How does Granules India compare with its peers?
On FY26 consolidated figures, against Aurobindo Pharma, Ipca Laboratories and Aarti Drugs: Granules India's operating margin of 16.6% is the highest of the four (Aurobindo Pharma 15.1%, Ipca Laboratories 16.2%, Aarti Drugs 9.4%; peer average 13.6%); its return on equity of 13.5% is the second highest of the four (Aurobindo Pharma 9.9%, Ipca Laboratories 15.2%, Aarti Drugs 13.4%; peer average 12.8%); its revenue growth over three years of 6.0% a year is the third highest of the four (Aurobindo Pharma 10.6% a year, Ipca Laboratories 15.6% a year, Aarti Drugs −1.9% a year; peer average 8.1% a year).
Granules India vs Aurobindo Pharma: how do they compare?
In FY26, Granules India earned net profit of ₹595 crore on revenue of ₹5,366 crore, against ₹3,505 crore on ₹33,653 crore for Aurobindo Pharma. Granules India's operating margin was 16.6% (Aurobindo Pharma 15.1%) and its return on equity 13.5% (Aurobindo Pharma 9.9%). At the 29 October 2026 close, Granules India's market capitalisation was ₹20,750 crore against ₹95,511 crore for Aurobindo Pharma, and its PE ratio on FY26 profit 34.9 against 27.3.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
